I agree completely- if the OxyC trials show promising results then POH will give it more attention and funding for development- POH as Harry said would then be embarking " on a new market for this class of (pain) products".
Roberts and others have suggested that any Pharma deal will take both OxyM an OxyC as a package- might we see interest from partners on the back of these OxyC Trials for the entire Pain portfolio- fingers crossed .
License, License Licence is POHs mantra in 2014
Chart, Cash and Scenarios, page-44
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.001(20.0%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $580 | 200K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 34 | 29443702 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 52585197 | 27 |
View Market Depth
| Last trade - 13.20pm 18/09/2024 (20 minute delay) ? |
| AVE (ASX) Chart |